Prevalence, Incidence, and Risk of Progression of Asymptomatic Pancreatic Cysts in Large Sample Real-world Data. Issue 9 (3rd October 2021)

• Record Type: Journal Article
• Authors: Schweber, Adam B.; Agarunov, Emil; Brooks, Christian; Hur, Chin; Gonda, Tamas A.
• Is Part Of: Pancreas. Volume 50:Issue 9(2021)
• Page Start: 1287
• Page End: 1292
• Publication Date: 2021-10-03
• Subjects: pancreatic cyst -- pancreatic cancer -- epidemiology -- prevalence -- progression risk -- real-world data; Pancreas -- Diseases -- Periodicals; Pancreas -- Periodicals; Neuroendocrine tumors -- Periodicals; 616.37005
• DOI: 10.1097/MPA.0000000000001918
• Languages: English
• ISSNs: 0885-3177

Abstract

Abstract : Supplemental digital content is available in the text. Abstract : Objectives: Using large-sample, real-world administrative claims data, we evaluated the prevalence of putatively asymptomatic pancreatic cysts, the historical growth in their incident diagnosis, and their risk of malignant progression. Methods: Data were sourced from IBM MarketScan administrative claims databases of more than 200 million patients. Period prevalence was assessed using 700, 000 individuals without conditions that predispose to pancreatic cyst. The standardized cumulative incidence was compared with the cross-sectional abdominal imaging rate from 2010–2017. The risk of progression to pancreatic cancer for 14, 279 newly diagnosed patients with a cyst was estimated using Kaplan-Meier analysis. Results: Standardized prevalence increased exponentially with age and was 1.84% (95% confidence interval, 1.80%–1.87%) for patients older than 45. Standardized incidence nearly doubled from 2010–2017 (6.3 to 11.4 per 10, 000), whereas the imaging rate changed from only 8.0% to 9.4%. The cumulative risk of pancreatic cancer at 7 years was 3.0% (95% confidence interval, 2.4%–3.5%), increasing linearly ( R 2 = 0.991) with an annual progression risk of 0.47%. Conclusions: Using large-sample data, we show a significant burden of asymptomatic pancreatic cysts, with an annual risk of progression to cancer of 0.47% for 7 years. Rapid growth in cyst diagnosis over the last decade far outpaced increases in the imaging rate.